NEW YORK, June 23, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Spero investors who were adversely affected by alleged securities fraud between October 28, 2021 and May 2, 2022. Follow the link below to get more information and be contacted by a member of our team:
https://www.zlk.com/pslra-1/spero-therapeutics-inc-loss-submission-form?prid=28964&wire=4
SPRO investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the data submitted in support of the New Drug Application ("NDA") for the Company's product candidate, Tebipenem HBr, were insufficient to obtain approval from the U.S. Food and Drug Administration ("FDA"); (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing would necessitate a significant workforce reduction and restructuring of Spero's operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Spero during the relevant time frame, you have until July 25, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/spro-lawsuit-alert-levi--korsinsky-notifies-spero-therapeutics-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-301573379.html
SOURCE Levi & Korsinsky, LLP
